Phase 2 N=40 Antineoplaston Therapy in Treating Patients With Brain Stem Glioma
Brain Stem Gliomas
Primary: Number of Participants With Objective Response — 5; 4; 8; 14 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=3 Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma
Glioma · Anaplastic Astrocytoma · Anaplastic Oligodendroglioma
Primary: Percentage of Dose-limiting Toxicities — 0; 0; 17 Percentage of dose-limiting toxicities
Phase 2 N=51 Tipifarnib and Radiation Therapy in Treating Young Patients With Brainstem Glioma
Untreated Childhood Brain Stem Glioma
Primary: Number of Participants in the Phase I Component With Dose-limiting Toxicities (DLTs) Observed During the First 8 Weeks (Courses 1 and 2) of Tipifarnib Therapy — 0; 1; 4…
Phase 2 N=32 A Phase II Study of Pegylated Interferon Alfa 2b (PEG-Intron(Trademark)) in Children With Diffuse Pontine Gliomas
Diffuse Intrinsic Pontine Glioma
Primary: Two Year Survival of Pediatric Patients With Diffuse Pontine Gliomas — 14.29 Percentage of patients
Phase 2 N=45 A Study of Capecitabine (Xeloda®) and Concomitant Radiation Therapy in Children With Newly Diagnosed Brainstem Gliomas
Brainstem Glioma
Primary: Progression-free Survival — 4.9 Months
N/A N=58 Functional Monitoring for Motor Pathway in Brain Tumor Surgery Within Eloquent Area
Glioma, Motor Pathway
Primary: Extent of Tumor Resection — 40; 7; 7; 4 participants
N/A N=22 Whole Brain Radiation Therapy With Boost to Metastatic Tumor Volume Using RapidArc
Neoplasm Metastasis
Primary: Percent of Participants With Locoregional Control of Treating Brain Metastasis Patients — 92; 98.6; 46; 46 percentage of participants
Phase 2 N=53 A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors
Central Nervous System Neoplasms · Medulloblastoma
Primary: Percentage of Participants With an Objective Response and Long-term Stable Disease — 0; 11.1; 10.5; 0 percentage of participants
Phase 2 N=41 O6-Benzylguanine and Temozolomide in Treating Young Patients With Recurrent or Progressive Gliomas or Brain Stem Tumors
Brain and Central Nervous System Tumors
Primary: Percentage of Participants With an Objective Response (Complete Response or Partial Response) — 4; 0 Percent of Participants
Phase 2 N=38 Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma
Glial Cell Tumors · Malignant Gliomas · Glioblastoma Multiforme
Primary: 1-year Event Free Survival (EFS) — 12; 24 percentage of participants — p=< 0.05
Phase 1 N=16 Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas
Adult Anaplastic Astrocytoma · Adult Anaplastic Oligodendroglioma · Adult Giant Cell Glioblastoma
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) and Maximum Tolerated Dose (MTD) — 0; 0; 0; 1 Participants
N/A N=52 MRI Study of Changes in Blood-Brain/Tumor-Barrier Permeability in Patients With Brain Metastases During and After Radiotherapy
Brain Metastases
Primary: Percentage of the Gross Tumor Volume With a BTB Opening of Ktrans > 0.005 Min-1 — 78.6; 85.6; 6.4; 74.4 percentage of gross tumor volume
N/A N=12 PET/CT Evaluation of Primary and Metastatic Brain Tumors With a Novel Radioiodinated Phospholipid Ether Analogue I-NM404
Glioblastoma Multiforme · Brain Metastases
Primary: Tumor to Background Ratios (TBR) Post-imaging for All Lesions With PET Uptake — 8.25; 8.75 Ratio of PET SUV
Phase 2 N=104 Neoadjuvant Chemotherapy With or Without Second-Look Surgery Followed by Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Intracranial Germ Cell Tumors
Brain Tumor · Central Nervous System Tumors · Childhood Germ Cell Tumor
Primary: Response to Induction Chemotherapy — 74; 11 Participants
Phase 2 N=42 Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors
Glioblastoma · Gliosarcoma · Anaplastic Astrocytoma
Primary: Progression-free Survival at 6 Months — 23 Percentage of participants
Phase 2 N=40 Antineoplaston Therapy in Treating Patients With Brain Tumors
Refractory Brain Tumors
Primary: Number of Participants With Objective Response — 4; 5; 12; 10 Participants
Phase 2 N=27 Bevacizumab in Pats w/ Recurrent ST Brain Metas Who Have Failed Whole Brain Radiation Therapy
Metastatic Cancer · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Objective Radiographic Tumor Response in Patients With Recurrent Solid Tumor Brain Metastases Treated With Bevacizumab — 2 Participants
Phase 2 N=15 Thalidomide and Temozolomide in Relapsed or Progressive CNS Disease or Neuroblastoma
Central Nervous System Tumor, Pediatric · Neuroblastoma
Primary: Therapy Completion Rate — .40 proportion of participants
Phase 2 N=40 Antineoplaston Therapy in Treating Patients With Primary Malignant Brain Tumors
Malignant Brain Tumors
Primary: Number of Participants With Objective Response — 2; 2; 4; 19 Participants
Phase 2 N=8 Combination of Hydroxyurea and Verapamil for Refractory Meningiomas
Cancer · Brain Cancer · Meningioma
Primary: Number of Participants Experiencing Serious Adverse Events Including But Not Limited to Hospitalizations, Deaths Related to Treatment, or Other Incapacitating…
Phase 2 N=43 Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors
Glioma
Primary: Response, Defined as Stable Disease or Objective (Partial or Complete) Response. — 0; 0; 0; 0 Participants
Phase 2 N=265 Brain Irradiation in Treating Patients With Limited-Stage Small Cell Lung Cancer
Lung Cancer
Primary: Incidence of Chronic Neurotoxicity — 60; 85; 89 percentage of participants
Phase 2 N=7 Phase II Trial of Peginterferon Alpha-2b and Thalidomide in Adults With Recurrent Gliomas
Glioma
Primary: Progression-free Survival
Phase 2 N=100 Proton Radiotherapy for Pediatric Brain Tumors Requiring Partial Brain Irradiation
Brain Tumor · Low Grade Glioma · Astrocytoma
Primary: Endocrine Dysfunction — 14.5; 20.2 percentage of participants
Phase 2 N=17 Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With Glioblastoma
Glioblastoma · Glioblastoma With Primitive Neuronal Component · Gliosarcoma
Primary: Proportion of Progression Free Survival Participants (PFS) at Six Months — 0.786 Proportion of participants
N/A N=90 Proton Beam Radiotherapy for Medulloblastoma and Pineoblastoma
Brain Tumor · Medulloblastoma · Pineoblastoma
Primary: Cumulative Incidence of Ototoxicity — 26; 27 percentage of participants
Phase 2 N=31 Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed GBM
Glioblastoma Multiforme · Brain Tumor
Primary: Progression-free Survival (PFS) — 91.3 percentage of participants
N/A N=13 Bevacizumab w / Temozolomide PET & Vascular MRI For GBM
Recurrent Glioblastoma
Primary: Number of Patients With a Decrease in Median Tumor SUV — 6 Participants
Phase 1 N=15 [F-18] Fluorothymidine (FLT) Imaging on Patients With Primary Brain Tumors
Cancer · Brain Tumors
Primary: Area Under the Receiver Operating Curve (ROC AUC) Values for PET Imaging Techniques — 0.98; 0.91; 0.89; 0.82 Probability
Phase 2 N=51 Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases
Brain Metastasis · Bladder Cancer · Breast Cancer
Primary: Local Control — 13; 23; 2; 1 participants